{
  "id": 15177672,
  "title": "Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.",
  "url": "https://urgent.news/2026/10/17/johnson-johnson-just-raised-its-sales-outlook-again-heres-why-the",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-17T10:15:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/17/johnson-johnson-raise-sales-dividend-king-buy/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Johnson & Johnson (JNJ) has raised its sales outlook for fiscal 2026, with operating sales growth now projected to be between 6.4% and 6.8%, up from the previous range of 6.2% to 6.8%. However, the company's medical technology equipment division underperformed, with revenue growing by only 2.5% to $8.6 billion, below analysts' expectations of over $8.7 billion. Despite this setback, J&J's overall sales and earnings guidance for the year remain robust. The company's medical tech division, which accounts for about one-third of its total sales and less than 20% of its adjusted net income, is not a significant liability. In fact, the orthopedics business within this division represents only about one-fourth of the medtech business. More importantly, J&J is on track to become the leading cancer treatment company by 2030, with global oncology sales expected to reach $7.6 billion in Q3 alone, up over 16% from the previous year. The FDA recently granted a priority review to one of J&J's key oncology drugs, Rybrevant, further bolstering the company's growth prospects. While the stock's recent volatility may deter some investors, the enduring strength of J&J's dividend and its long-term growth potential make it a compelling long-term investment.",
  "summary": "The guidance bump doesn't matter nearly as much as investors' response to the company's Q3 report suggests.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.",
        "url": "https://urgent.news/2026/10/17/johnson-johnson-just-raised-its-sales-outlook-again-heres-why-the-15192959",
        "published": "2026-10-17T10:35:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}